89zr bevacizumab - a radioimmunoconjugate comprised of the recombinant humanized monoclonal antibody bevacizumab labeled with the radioisotope zirconium zr 89 (zr 89) with radioisotopic activity and potential imaging use. The antibody moiety of zirconium zr 89 bevacizumab targets and binds to the extracellular domain of the vascular endothelial growth factor receptor (vegfr). Upon binding, the radioisotope moiety may be detected using positron emission tomography (pet), allowing the imaging and quantification of vegfr expressing tumor cells. Vegfr, a tyrosine kinase, is overexpressed on the cell surfaces of various tumor cell types.
Up to date info
Latest research - 89zr bevacizumab
Source: Data courtesy of the U.S. National Library of Medicine. Since the data might have changed, please query MeSH on 89zr bevacizumab for any updates.